Cynata Therapeutics (CYP) Q1 2027 TU earnings summary

Executive summary

• Cost reductions reshaped operations: all employee positions were made redundant, service-provider work was curtailed, and the Board is assessing development pathways and strategic options for the Cymerus platform.

Financial highlights

• Quarter-end cash was $175k; net operating cash outflow was $1.316m, including $334k for R&D, $823k for staff costs and $143k for administration and corporate costs.

• Related-party payments of $273k comprised salary and termination payments to the former Managing Director.

• Subsequent to quarter end, a $1.694m FY2026 R&D tax refund was received; after repaying the loan, net proceeds were $1.067m.

Outlook and guidance

• Following the cost cuts and expected entitlement-offer proceeds, cash runway is expected to extend into FY2028.

• Board priorities include evaluating future development pathways for Cymerus, seeking to realise value from the technology and considering rights to new assets.